Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial - Ebata, S; Yoshizaki, A; Oba, K (The Lancet Rheumatology, 2022)